Skip to main content

Research Repository

Advanced Search

The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England

Harrison, Graham I.; Murray, Karen; Gore, Roxanne; Lee, Penelope; Sreedharan, Aravamuthan; Richardson, Paul; Hughes, Amanda J.; Wiselka, Martin; Gelson, Will; Unitt, Esther; Ratcliff, Karen; Orton, Annette; Trinder, Kerry; Simpson, Charlotte; Ryder, Stephen D.; Oelbaum, Sandra; Foster, Graham R.; Archie, Christian; Smith, Stuart; Thomson, Brian J.; Reynolds, Rosy; Harris, Magdalena; Hickman, Matthew; Irving, William L.


Graham I. Harrison

Karen Murray

Roxanne Gore

Penelope Lee

Aravamuthan Sreedharan

Paul Richardson

Amanda J. Hughes

Martin Wiselka

Will Gelson

Esther Unitt

Karen Ratcliff

Annette Orton

Kerry Trinder

Charlotte Simpson

Stephen D. Ryder

Sandra Oelbaum

Graham R. Foster

Christian Archie

Stuart Smith

Brian J. Thomson

Rosy Reynolds

Magdalena Harris

Matthew Hickman


Background and Aims: Previous studies have shown low rates of diagnosis and treatment of hepatitis C virus (HCV) infection in people who inject drugs (PWID). Our aims were to test the effect of a complex intervention (“HepCATT”) in drug and alcohol clinics – primarily, on engagement of HCV-positive PWID with therapy, and, secondarily, on testing for HCV, referral to hepatology services, and start of HCV treatment.
Design and setting: A non-randomised pilot study in three specialist addiction clinics in England comparing an intervention year (starting between September 2015 and February 2016) with a baseline year (2014), together with three control clinics.
Participants: Analysis included a total of 5,225 PWID, of whom 1,055 were identified as HCVpositive.
Intervention: A half-time facilitator placed in each clinic undertook various activities, which could include training of key workers, direct interaction with clients, streamlining and support for hepatology appointments, and introduction of dried blood-spot testing.
Measurements: For each clinic and period, we obtained the total number of clients and, as relevant, their status as PWID, tested for HCV, known HCV-positive, engaged with HCV therapy, or treated.
Findings: Compared to baseline, there is strong evidence that engagement with HCV therapy in the intervention year increased (p less than 0.001) more in the HepCATT centres than controls, up +31 percentage points (95% CI 19 to 43) vs ‐12 (CI ‐31 to +6) and odds ratio 9.99 (CI 4.42–22.6) vs 0.35 (CI 0.08–1.56). HepCATT centres also had greater increases in HCV testing (OR 3.06 vs 0.78, p less than 0.001), referral to hepatology (OR 9.60 vs 0.56, p less than 0.001) and treatment initiation (OR 9.5 vs 0.74, p less than 0.001).
Introducing a half‐time facilitator into drug and alcohol clinics in England increased engagement of HCV‐positive people who inject drugs with hepatitis C virus care pathways, with increased uptake also of testing, referral to hepatology and initiation of treatment.


Harrison, G. I., Murray, K., Gore, R., Lee, P., Sreedharan, A., Richardson, P., …Irving, W. L. (2019). The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction, 114(6), 1113-1122.

Journal Article Type Article
Acceptance Date Jan 8, 2019
Online Publication Date Jan 29, 2019
Publication Date Jun 30, 2019
Deposit Date Jan 25, 2019
Publicly Available Date Jan 30, 2020
Journal Addiction
Print ISSN 0965-2140
Electronic ISSN 1360-0443
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 114
Issue 6
Pages 1113-1122
Public URL
Publisher URL